<table>
<thead>
<tr>
<th>Name</th>
<th>CTS Affiliation</th>
<th>Disclosure</th>
<th>Updated</th>
</tr>
</thead>
</table>
| Darcy Marciniuk     | • Alpha-1 Antitrypsin Deficiency Expert Working Group (Chair)  
|                     | • COPD Clinical Assembly                                                         | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
|                     |                                                                                 | • **Advisory Board/Consultation:** AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Health Canada, Health Quality Council, Novartis, Nycomed, Pfizer, Public Health Agency of Canada, Saskatchewan Medical Association, Saskatoon Health Region  
|                     |                                                                                 | • **Employment:** University of Saskatchewan  
|                     |                                                                                 | • **Fiduciary Positions:** American College of Chest Physicians, Canadian COPD Alliance, Chest Foundation, Saskatchewan Lung Association  
|                     |                                                                                 | • **Research Funding:** AstraZeneca, Boehringer-Ingelheim, Canadian Agency for Drugs and Technology in Health, CIHR, Forest Research, GlaxoSmithKline, Lung Association of Saskatchewan, Novartis, Nycomed, Pfizer, Saskatchewan Health Research Foundation, Saskatchewan Ministry of Health, Schering-Plough  
|                     |                                                                                 | • **Speaker/Honoraria:** AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Pfizer                                                                                                                                                                                                                                                                                                                                                   | November 23, 2011|
| Meyer Balter        | • Alpha-1 Antitrypsin Deficiency Expert Working Group  
|                     | • COPD Clinical Assembly                                                         | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
|                     |                                                                                 | • **Advisory Board:** AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed  
<p>|                     |                                                                                 | • <strong>Speaker/Honoraria:</strong> AstraZeneca, Bayer, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Nycomed, Pfizer                                                                                                                                                                                                                                                                                                                   | December 1, 2011 |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>CTS Affiliation</th>
<th>Disclosure</th>
<th>Updated</th>
</tr>
</thead>
</table>
| Jean Bourbeau     | • Alpha-1 Antitrypsin Deficiency Expert Working Group  
                        • COPD Clinical Assembly                                                           | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
  • **Advisory Board/Consultation:** Agence de santé et des services sociaux de Montréal, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Nycomed, Theratechnologies, Talecris  
  • **Conferences:** Agence de santé et des services sociaux de Montréal, MUHC, ACCP, APQ, ATS, ERS, Canadian Thoracic Society/Canadian Lung Association, Respiratory Health Network of the FRSQ, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Nycomed  
  • **Employment:** McGill University, fortaits and fees for service from the Régie de l’assurancemaladie du Québec (RAMQ)  
  • **Research Funding:** Research Institute of the McGill University Health Centre from CIHR, FRSQ, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer, Theratechnologies | January 9, 2012 |
| Andrew Cave       | • External Reviewer                                                                 | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
  • **Honoraria:** AstraZeneca  
  • **Research Funding:** Grifols                                                                                                                                                                                                 | February 6, 2012 |
| Kenneth Chapman   | • Alpha-1 Antitrypsin Deficiency Expert Working Group                           | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
  • **Academia:** CIHR-GSK Research Chair in Respiratory Healthcare Delivery, University Health Network  
  • **Advisory Board/Membership:** Alpha-1 Canada Medical Advisory Board; Alpha-1 Foundation Research Grants Committee; Canadian Alpha-1 Registry (AIR Canada; Director); AIR Member of Council; CIHR Postdoctoral Fellowship Review Committee; COPD Canada Medical Advisory Board; Canadian Network for Respiratory Care (President); Ontario College of Physicians and Surgeons (Peer Assessor); Ontario College of Physicians and Surgeons (Medical Inspector)  
  • **Employment:** University of Toronto (Professor of Medicine); University | November 10, 2011 |
<table>
<thead>
<tr>
<th>Name</th>
<th>CTS Affiliation</th>
<th>Disclosure</th>
<th>Updated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donna Goodridge</td>
<td>• COPD Clinical Assembly (Co-Chair)</td>
<td>Over the last two years, I have <strong>not</strong> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</td>
<td>January 5, 2012</td>
</tr>
<tr>
<td>Name</td>
<td>CTS Affiliation</td>
<td>Disclosure</td>
<td>Updated</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
</tbody>
</table>
| Paul Hernandez      | • Alpha-1 Antitrypsin Deficiency Expert Working Group  
• COPD Clinical Assembly (Chair)                                             | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
• **Advisory Board/Professional Development/Research/Speaker/Honoraria**: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer, Actelion, Lilly, CSL Behring  
• **Employment**: Dalhousie University (Associate Professor of Medicine)  
• **Research Funding**: CIHR, NSERC, SSHRC  
• **Reviewer**: Canadian Agency for Drugs and Technology in Health  
• **Volunteer**: Canadian Thoracic Society, Lung Association of Nova Scotia | December 14, 2011 |
| Julie Lauzon        | • Alpha-1 Antitrypsin Deficiency Expert Working Group                           | Over the last two years, I have not had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest. | December 16, 2011 |
| François Maltais    | • Alpha-1 Antitrypsin Deficiency Expert Working Group                           | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
• **Academia**: CIHR-GSK Research Chair on COPD  
• **Advisory Board**: GlaxoSmithKline, Boehringer-Ingelheim  
• **Research Grant**: GlaxoSmithKline, Boehringer-Ingelheim, AltanaPharma, Merck, AstraZeneca, Nycomed, Novartis  
• **Speaker/Honoraria**: Boehringer-Ingelheim, Pfizer, GlaxoSmithKline, Grifols | January 9, 2012 |
| Denis O'Donnell     | • Alpha-1 Antitrypsin Deficiency Expert Working Group  
• COPD Clinical Assembly                                                  | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
• **Advisory Board**: Boehringer-Ingelheim, Pfizer Canada, AstraZeneca  
• **Consultation**: Boehringer-Ingelheim, Pfizer Canada, GlaxoSmithKline  
• **Research Grant**: Boehringer-Ingelheim, Pfizer Canada, GlaxoSmithKline, Novartis  
• **Speaker/Honoraria**: Boehringer-Ingelheim, Pfizer Canada, GlaxoSmithKline | November 24, 2011 |
<table>
<thead>
<tr>
<th>Name</th>
<th>CTS Affiliation</th>
<th>Disclosure</th>
<th>Updated</th>
</tr>
</thead>
</table>
| Charlie Strange | • External Reviewer | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
• **Consultant:** TalecrisBiotherapeutics, CSL Behring  
• **Research Grants:**Alpha-1 Foundation, Alpha-1 Association, TalecrisBiotherapeutics, National Institutes of Health (NIH)  
• **Speaker/Honoraria:** TalecrisBiotherapeutics | February 15, 2012 |